Viridian Therapeutics, Inc.\DE (VRDN) Non-Current Deffered Revenue (2021 - 2025)
Viridian Therapeutics, Inc.\DE (VRDN) posted quarterly Non-Current Deffered Revenue of $140000.0 for Q2 2025, down 67.29% year-over-year from $428000.0 in Q2 2024, and down 33.96% quarter-over-quarter from $212000.0 in Q1 2025.
Powered by 
Analysis
Viridian Therapeutics, Inc.\DE (VRDN) Non-Current Deffered Revenue (2021 - 2025) Analysis & Trends
Viridian Therapeutics, Inc.\DE's Non-Current Deffered Revenue history runs 5 years deep, the most recent figure standing at $140000.0 for Q2 2025.
- In Q2 2025, Non-Current Deffered Revenue fell 67.29% year-over-year to $140000.0; the TTM figure through Jun 2025 stood at $140000.0 (down 67.29% YoY), while the FY2024 annual figure was $284000.0, down 50.44% from the prior year.
- Non-Current Deffered Revenue for Q2 2025 stood at $140000.0, down from $212000.0 in the prior quarter.
- The five-year high for Non-Current Deffered Revenue was $1.1 million in Q4 2021, with the low at $140000.0 in Q2 2025.
- The 5-year median for Non-Current Deffered Revenue is $645000.0 (2023), against an average of $644600.0.
- The sharpest annual moves came in 2022 and 2025: Non-Current Deffered Revenue retreated 25.07% in 2022, then slumped 67.29% in 2025.
- Viridian Therapeutics, Inc.\DE's Non-Current Deffered Revenue stood at $1.1 million in 2021, then dropped by 25.07% to $861000.0 in 2022, then tumbled by 33.45% to $573000.0 in 2023, then tumbled by 50.44% to $284000.0 in 2024, then plunged by 50.7% to $140000.0 in 2025.
- Business Quant data shows VRDN's Non-Current Deffered Revenue at $140000.0 in Q2 2025, $212000.0 in Q1 2025, and $284000.0 in Q4 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 147.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Viridian Therapeutics, Inc.\DE | 2.42 Bn | 2.42 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2025 | 140,000.00 |
| Mar 31, 2025 | 212,000.00 |
| Dec 31, 2024 | 284,000.00 |
| Sep 30, 2024 | 356,000.00 |
| Jun 30, 2024 | 428,000.00 |
| Mar 31, 2024 | 500,000.00 |
| Dec 31, 2023 | 573,000.00 |
| Sep 30, 2023 | 645,000.00 |
| Jun 30, 2023 | 717,000.00 |
| Mar 31, 2023 | 789,000.00 |
| Dec 31, 2022 | 861,000.00 |
| Sep 30, 2022 | 933,000.00 |
| Jun 30, 2022 | 1.01 Mn |
| Mar 31, 2022 | 1.08 Mn |
| Dec 31, 2021 | 1.15 Mn |